1. Peto R, zur Hausen H, eds. Viral origin of cervical cancer. Bambury report no. 21, New York: Cold Spring Harbor CSH Press, 1986.
2. Franco EL. The sexually transmitted disease model for cervical cancer: incoherent epidemiologic findings and the role of misclassification of human papillomavirus infection. Epidemiology 1991;2:98–106. [PubMed] 3. Bosch FX, Muñoz N, de Sanjosé S, et al. Risk factors for cervical cancer in Colombia and Spain. Int J Cancer 1992;52:750–58. [PubMed] 4. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958–64. [PubMed] 5. Thomas DB, Ray RM, Koetsawang A, et al. Human papillomaviruses and cervical cancer in Bangkok. I. Risk factors for invasive cervical carcinomas with human papillomavirus types 16 and 18 DNA. Am J Epidemiol 2001;153:723–31. [PubMed] 6. Lilienfeld AM. On the methodology of investigations of etiologic factors in chronic disease—some comments. J Chronic Dis 1959;10:41–6. [PubMed] 7. Sartwell PE. On the methodology of investigations of etiologic factors in chronic disease—further comments. J Chronic Dis 1960;11:61–3. [PubMed] 8. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965;58:295–300. [PMC free article] [PubMed]
9. Surgeon General's Advisory Committee on Smoking and Health. DHEW publication no. (PHS) 1103. MD, USA: US Public Health Service, 1964.
10. Susser M. Causal thinking in the health sciences. New York: Oxford University Press, 1973.
11. MacMahon B, Pugh TF. Concepts of causes. In: Epidemiology: principles and methods. Boston: Little, Brown, 1970:17–29.
12. IARC. Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans, Vol. 64. Lyon: IARC, 1995. [PubMed]
13. Weed DL. Causal and preventive inference. In: Greenwald P, Kramer BS, Weed DL, eds. Cancer prevention and control. New York: M Dekker, 1995:285–302.
14. Evans AS. Causation and disease: the Henle-Koch postulates revisited. Yale J Biol Med 1976;49:175–95. [PMC free article] [PubMed] 15. Rothman KJ. Causes. Am J Epidemiol 1976;104:587–92. [PubMed]
16. Shah KV, Howley PM. Papillomaviruses. In: Knipe DM, Howley PM, eds. Fields virology. Philadelphia: Lippincott-Raven, 1996:2077–109.
17. zur Hausen H. Papillomavirus causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000;92:690–98. [PubMed]
18. Rothman KJ. Reviews and commentary. Causes. Am J Epidemiol 1995;104:90–5.
19. Rothman KJ. Causal inference in epidemiology. In: Rothman KJ. Modern epidemiology. Boston, Toronto: Little, Brown and Company, 1986:7–23.
20. Gravitt PE, Manos MM. Polymerase chain reaction-based methods for the detection of human papillomavirus DNA, Vol. 119. Lyon: IARC Scientific Publications, 1992. [PubMed] 21. van den Brule AJC, Meijer CJLM, Bakels V, et al. Rapid human papillomavirus detection in cervical scrapes by combined general primer mediated and type-specific polymerase chain reaction. J Clin Microbiol 1991;28:2739–43. [PMC free article] [PubMed] 22. de Roda Husman AM, Walboomers JMM, van den Brule AJC, et al. The use of general primers GP5 and GP6 elongated at their 3` ends with adjacent highly conserved sequences improves human papillomavirus detection by polymerase chain reaction. J Gen Virol 1995;76:1057–62. [PubMed] 23. Bosch FX, Rohan T, Schneider A, et al. Papillomavirus research update: highlights of the Barcelona HPV 2000 international papillomavirus conference. J Clin Pathol 2001;54:163–75. [PMC free article] [PubMed] 24. Muñoz N, Bosch FX, de Sanjosé SM, et al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer 1992;52:743–9. [PubMed] 25. Eluf-Neto J, Booth M, Muñoz N, et al. Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer 1994;69:114–19. [PMC free article] [PubMed] 26. Chaouki N, Bosch FX, Muñoz N, et al. The viral origin of cervical cancer in Rabat, Morocco. Int J Cancer 1998;75:546–54. [PubMed] 27. Rolón PA, Smith JS, Muñoz N, et al. Human papillomavirus infection and invasive cervical cancer in Paraguay. Int J Cancer 2000;85:486–91. [PubMed] 28. Ngelangel C, Muñoz N, Bosch FX, et al. Causes of cervical cancer in the Philippines: a case-control study. J Natl Cancer Inst 1998;90:43–9. [PubMed] 29. Chichareon S, Herrero R, Muñoz N, et al. Risk factors for cervical cancer in Thailand: a case control study. J Natl Cancer Inst 1998;90:50–7. [PubMed] 30. Santos C, Munoz N, Klug S, et al. HPV types and cofactors causing cervical cancer in Peru. Br J Cancer 2001;85:966–71. [PMC free article] [PubMed] 31. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831–6. [PubMed] 32. Muñoz N, Bosch FX, Chichareon S, et al. A multinational case-control study on the risk of cervical cancer linked to 25 HPV types: which are the high-risk types? In: Castellsagué X, Bosch FX, de Sanjosé S, et al, eds. 18th International Papillomavirus Conference—program and abstracts book. Barcelona: Thau SL, 2000:125 (available on line: http:/www.hpv2000.com). 33. Bosch FX, Muñoz N, Chichareon S, et al. HPV and cervical adenocarcinoma: an IARC based multicentric case-control study. In: Castellsagué X, Bosch FX, de Sanjosé S, et al, eds. 18th International Papillomavirus Conference—program and abstracts book. Barcelona: Thau SL, 2000:131 (available on line: http:/www.hpv2000.com). 34. Bosch FX, Manos MM, Muñoz N, et al. Prevalence of human papillomavirus cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;87:796–802. [PubMed] 35. Castellsagué X, Menéndez C, Loscertales M-P, et al. Human papillomavirus genotypes in rural Mozambique. Lancet 2001;358:1429–30. [PubMed] 36. Herrero R, Muñoz N, Lazcano E, et al. HPV International prevalence surveys in general populations. In: Castellsagué X, Bosch FX, de Sanjosé S, et al, eds. 18th International Papillomavirus Conference—program and abstracts book. Barcelona: Thau SL, 2000:126 (available on line: http:/www.hpv2000.com). 37. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464–74. [PubMed] 38. Thomas DB, Quin Q, Kuypers J, et al. Human papillomaviruses and cervical cancer in Bangkok. II. Risk factors for in situ and invasive squamous cell cervical carcinomas. Am J Epidemiol 2001;153:732–8. [PubMed] 39. Olsen AO, Gjoen K, Sauer T, et al. Human papillomavirus in cervical intraepithelial neoplasia grade II-III: a population-based case-control study. Int J Cancer 1995;61:312–15. [PubMed] 40. Kjaer SK, Van den Brule AJC, Boch JE, et al. Human papillomavirus—the most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer 1996;65:601–6. [PubMed] 41. de Sanjose S, Valls I, Cañadas MP, et al. Infección por los virus del papiloma humano y de la inmunodeficiencia humana como factores de riesgo para el cáncer de cuello uterino en mujeres reclusas. Med Clin (Barc) 2000;115:81–4. [PubMed] 42. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999;91:226–36. [PubMed] 43. Beasley RP, Lin CH, Hwang L-Y, et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981;21:1129–31. [PubMed] 44. Kuper HE, Tzonou A, Kaklamari E, et al.Hepatitis B and viruses in the etiology of hepatocellular carcinoma; a study in Greece using third-generation assays: Cancer Causes Control 2000;11:171–5. [PubMed] 45. Donato F, Tagger A, Chiesa R, et al. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control in study Italy. Hepatology 1997;26:579–84. [PubMed] 46. Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000;321:323–9. [PMC free article] [PubMed] 47. Lee M-S, Kim D-H, Kim H, et al. Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: a cohort study in Korea. Int J Epidemiol 1998;27:316–19. [PubMed] 48. Chang M-H, Chen CH-J, Lai M-S, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336:1855–907. [PubMed] 49. Moreno V, Muñoz N, Bosch FX, et al. Risk factors for progression of cervical intraepithelial neoplasm grade III to invasive cervical cancer. Cancer Epidemiol Biomarkers Prev 1995;4:459–67. [PubMed] 50. Asato T, Nakajima Y, Nagamine M, et al. Correlation between the progression of cervical dysplasia and the prevalence of human papillomavirus. J Infect Dis 1994;169:940–1. [PubMed] 51. Shen C-Y, Ho M-S, Chang S-F, et al. High rate of concurrent genital infections with human cytomegalovirus and human papillomaviruses in cervical cancer patients. J Infect Dis 1993;168:449–52. [PubMed] 52. Arends MJ, Donaldson YK, Duval E, et al. Human papillomavirus type 18 associates with more advanced cervical neoplasia than human papillomavirus type 16. Hum Pathol 1993;24:432–7. [PubMed] 53. Das BC, Sharma JK, Gopalkrishna V, et al. A high frequency of human papillomavirus DNA sequences in cervical carcinomas of Indian women as revealed by Southern blot hybridization and polymerase chain reaction. J Med Virol 1992;36:239–45. [PubMed] 54. Ter Meulen J, Eberhardt HC, Luande J, et al. Human papillomavirus (HPV) infection, HIV infection and cervical cancer in Tanzania, East Africa. Int J Cancer 1992;51:515–21. [PubMed]
55. Muñoz N, Bosch FX. HPV and cervical neoplasia: review of case-control and cohort studies. In: Muñoz N, Bosch FX, Shah KV, et al, eds. The epidemiology of cervical cancer and human papillomavirus. Lyon: IARC Scientific Publications No. 119, 1992:251–6.
56. Peng HQ, Liu Sl, Mann V, et al. Human papillomavirus types 16 and 33, herpes simplex virus type 2 and other risk factors for cervical cancer in Sichuan Province, China. Int J Cancer 1991;47:711–16. [PubMed] 57. Griffin NR, Bevan IS, Lewis FA, et al. Demonstration of multiple HPV types in normal cervix and in cervical squamous cell carcinoma using the polymerase chain reaction on paraffin wax embedded material. J Clin Pathol 1990;43:52–6. [PMC free article] [PubMed] 58. Marin J, Ursic Vrscaj M, Erzen M. Detection of human papillomaviruses (HPV-16,18) in cervical smears by in situ hybridization. Israel J Med Sci 1994;30:448–50. [PubMed] 59. Lörincz AT, Reid R, Jenson AB, et al. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992;79:328–37. [PubMed] 60. Kanetsky PA, Mandelblatt J, Richart R, et al. Risk factors for cervical cancer in a black, elderly population: preliminary findings. Ethn Dis 1992;2:337–42. [PubMed] 61. Kadish AS, Hagan RJ, Ritter DB, et al. Biologic characteristics of specific human papillomavirus types predicted from morphology of cervical lesions. Hum Pathol 1992;23:1262–9. [PubMed] 62. Mandelblatt J, Richart R, Thomas L, et al. Is human papillomavirus associated with cervical neoplasia in elderly? Gynecol Oncol 1992;46:6–12. [PubMed] 63. Saito J, Fukuda T, Nakatani H, et al. Detection of human papillomavirus DNA in the normal cervices of Japanese women by the dot-blot (Vira PapTM) method. Asia-Oceania J Obstet Gynaecol 1992;18:283–7. [PubMed] 64. Ohta M, Casanova H, Mizuno K, et al. Epidemiologic background and changes in patients infected with human papilloma virus. Nippon Sanka Fujinka Gakkai Zasshi 1991;43:479–84. [PubMed] 65. Wei Z, Yazhou S, Shunqian J, et al. The association between cervical carcinoma and human papilloma virus (HPV) in Xiangyuan county. Chin Med Sci J 1991;6:74–7. [PubMed] 66. Si JY, Lee K, Han R, et al. A research for the relationship between human papillomavirus and human uterine cervical carcinoma. I. The identification of viral genome and subgenomic consequences in biopsies of Chinese patients. J Cancer Res Clin Oncol 1991;117:454–9. [PubMed] 67. Chang F, Syrjänen S, Shen Q, et al. Detection of human papillomavirus (HPV) in genital warts and carcinomas by DNA in situ hybridization in Chinese patients. Cytopathology 1990;1:97–103. [PubMed] 68. Zhang GA. A study on the relationship between human papilloma virus (HPV) and cervical cancer. Chinese Journal of Epidemiology 1990;11:31–3. [PubMed] 69. Yokota H, Yoshikawa H, Shiromizu K, et al. Detection of human papillomavirus types 6/11, 16 and 18 in exfoliated cells from the uterine cervices of japanese women with and without lesions. Jpn J Cancer Res 1990;81:896–901. [PubMed] 70. Colgan TJ, Percy ME, Suri M, et al. Human papillomavirus infection of morphologically normal cervical epithelium adjacent to squamous dysplasia and invasive carcinoma. Hum Pathol 1989;20:316–19. [PubMed] 71. Czeglédy J, Gergely L, Hernádi Z, et al. Detection of human papillomavirus deoxyribonucleic acid in the female genital tract. Med Microbiol Immunol (Berl) 1989;178:309–14. [PubMed] 72. Reeves WC, Brinton LA, Garcia M, et al. Human papillomavirus infection and cervical cancer in Latin America. N Engl J Med. 1989;320:1437–41. [PubMed] 73. Donnan SPB, Wong FWS, Ho SC, et al. Reproductive and sexual risk factors and human papilloma virus infection in cervical cancer among Hong Kong. Chinese International Journal of Epidemiology 1989;18:32–6. [PubMed] 74. Zhang WH, Coppleson M, Rose BR, et al. Papillomavirus and cervical cancer; a clinical and laboratory study. J Med Virol 1988;26:163–74. [PubMed] 75. Wilczynski SP, Walker J, Liao S-Y, et al. Adenocarcinoma of the cervix associated with human papillomavirus. Cancer 1988;62:1331–6. [PubMed] 76. Fuchs PG, Girardi F. Pfister human papillomavirus DNA in normal, metaplastic, preneoplastic and epithelia of the cervix uteri. Int J Cancer 1988;41:41–5. [PubMed] 77. Hsieh CY, Lee S-C, Huang S-C. Presence and expression of human papillomavirus types 16 and 18 DNA sequences in cervical carcinomas. Asia-Oceania J Obstet Gynaecol 1988;14:87–95. [PubMed] 78. Choo K-B, Shen H-D, Leung W-Y, et al. A distinct difference in the prevalence of papillomavirus infection in cytologically normal and neoplastic cells of the uterine cervix. Chinese Med J (Taipei) 1988;42:1–6. [PubMed] 79. Kulski JK, Howard MJ, Pixley. ECDNA sequences of human papillomavirus types 11, 16 or 18 in invasive cervical carcinoma of Western Australian women. Immunol Cell Biol 1987;65:77–84. [PubMed] 80. Zhang WH, Wu AR, Li JX, et al. Relation between human papillomavirus (HPV) and cancer of uterine cervix. Chinese Journal of Oncology 1987;9:433–5. [PubMed] 81. Lörincz AT, Temple GF, Kurman RJ, et al. Oncogenic association of specific human papillomavirus types with cervical neoplasia. J Natl Cancer Inst 1987;79:671–7. [PubMed] 82. Schneider A , de Villiers E-M, Schneider V. Multifocal squamous neoplasia of the female genital tract: significance of human papillomavirus infection of the vagina after hysterectomy. Obstet Gynecol 1987;70:294–8. [PubMed] 83. Meanwell CA, Cox MF, Blackledge G, et al. HPV 16 DNA in normal and malignant cervical epithelium: implications for the aetiology and behaviour of cervical neoplasia. Lancet 1987;1:703–7. [PubMed] 84. McCance DJ, Campion MJ, Clarkson PK, et al. Prevalence of human papillomavirus type 16 DNA sequences in cervical intraepithelial neoplasia and invasive carcinoma of the cervix. Br J Obstet Gynaecol 1985;92:1101–5. [PubMed] 85. Josefsson AM, Agnetha M, Magnusson PKE, et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000;355:2189–93. [PubMed] 86. Ylitalo N, Josefsson A, Melbye M, et al. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res 2000;60:6027–32. [PubMed] 87. Lacey JV, Frisch M, Brinton LA, et al. Association between smoking and adenocarcinomas and squamous cell carcinomas of the uterine cervix (United States). Cancer Causes Control 2001;12:153–61. [PubMed] 88. van Beurden M, ten Kate FWJ, Smits HL, et al. Multifocal vulvar intraepithelial neoplasia grade III and multicentric lower genital tract neoplasia is associated with transcriptionally active human papillomavirus. Cancer 1995;75:2879–84. [PubMed] 89. van Beurden M, ten Kate FWJ, Tjong-A-Hunt SP, et al. Human papillomavirus DNA in multicentric vulvar intraepithelial neoplasia. Int J Gynecol Pathol 1998;17:12–16. [PubMed] 90. Pinto AP, Signorello LB, Crum CP, et al. Squamous cell carcinoma of the vulva in brazil: prognostic importance of host and viral variables. Gynecol Oncol 1999;14:61–7. [PubMed] 91. Brandsman JL, Abramson AL. Association of papillomavirus with cancers of the head and neck. Arch Otolaryngol Head Neck Surg 1989;115:621–5. [PubMed] 92. Snijders PJF, Cromme FV, van der Brule AJC, et al. Prevalence and expression of human papillomavirus in tonsillar carcinomas, indicating a possible viral etiology. Int J Cancer 1992;51:845–50. [PubMed] 93. Cruz IBF, Snijders PJF, Steenbergen RDM, et al. Age-dependence of human papillomavirus DNA presence in oral squamous cell carcinomas. Eur J Cancer Oral Oncol 1996;32B:55–62. [PubMed] 94. Frisch M, Biggar RJ. Aetiological parallel between tonsillar and anogenital squamous-cell carcinomas: Lancet 1999;354:1442–5. [PubMed] 95. Harwood CA, Surentheran T, McGregor JM, et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000;61:289–97. [PubMed] 96. Newton RA. review of the aetiology of squamous cell carcinoma of the conjunctiva. Br J Cancer 1996;74:1511–13. [PMC free article] [PubMed] 97. Xi LF, Koutsky LA, Galloway DA, et al. Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst 1997;89:796–802. [PubMed] 98. Villa LL, Sichero L, Rahal P, et al. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol 2000;81:2959–68. [PubMed] 99. Hildesheim A, Schiffman M, Bromley C, et al. Human papillomavirus type 16 variants and risk of cervical cancer. J Natl Cancer Inst 2001;93:315–18. [PubMed]
100. Syrjänen K, Syrjänen S. HPV infections in other sites and lesions. In: Infections in human pathology. UK: Wiley 1999:445–56.
101. Lazcano-Ponce E, Herrero R, Muñoz N, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001;91:1–9. [PubMed] 102. Melkert PW, Hopman E, van den Brule AJ, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer 1993;53:919–23. [PubMed] 103. Bauer HM, Hildesheim A, Schiffman MH, et al. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis 1993;20:274–8. [PubMed] 104. Bosch FX, Muñoz N, de Sanjosé S, et al. Importance of human papillomavirus endemicity in the incidence of cervical cancer: an extension of the hypothesis on sexual behavior. Cancer Epidemiol Biomarkers Prev 1994;3:375–9. [PubMed] 105. Kjaer SK, Van der Brule AJC, Boch JE, et al. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiol Biomarkers Prev 1997;6:799–805. [PubMed] 106. Jacobs MV, Walboomers JMM, Snijders PJF, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000;87:221–7. [PubMed] 107. Schneider A, Hoyer H, Lotz B, et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 2000;89:529–34. [PubMed]
108. Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents. Lyon: IARC Scientific Publications, Vol. VII, No 143, 1997.
109. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415–23. [PubMed] 110. Ho GYF, Biermal R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423–28. [PubMed] 111. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272–8. [PubMed] 112. Ho GYF, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365–71. [PubMed] 113. Remmink AJ, Walboomers JM, Helmerhorst TJ, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995;61:306–11. [PubMed] 114. Nobbenhuis MAE, Walboomers JMM, Helmerhorst TJM, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20–5. [PubMed] 115. Rozendaal L, Walboomers JM, van der Linden JC, et al. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 1996;68:766–9. [PubMed] 116. Rozendaal L, Westerga J, van der Linden JC, et al. PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. J Clin Pathol 2000;53:606–11. [PMC free article] [PubMed] 117. Zielinski GD, Snijders PJF, Rozendaal L, et al. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer 2001;85:398–404. [PMC free article] [PubMed] 118. Nobbenhuis MAE, Helmerhorst THJM, van den Brule AJC, et al. Cytological regression and clearance of high-risk human papillomavirus in women with abnormal cervical smear. Lancet 2001;358:1782–3. [PubMed] 119. Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999;281:1605–10. [PubMed] 120. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001;286:3106–14. [PubMed] 121. Zielinski GD, Snijders PJF, Rozendaal L, et al. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance. J Clin Pathol 2001;193:1–8. [PubMed] 122. Nobbenhuis MA, Meijer CJ, van den Brule AJ, et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001;84:796–801. [PMC free article] [PubMed] 123. Wallin K-L, Wiklund F, Angström T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633–8. [PubMed] 124. Dillner J, Lehtinen M, Bjorge T, et al. Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst 1997;89:1293–9. [PubMed] 125. Campion MJ, McCance DJ, Cuzick J, et al. Progressive potential of mild cervical atypia; prospective cytological, colposcopic, and virological study. Lancet 1986;2:237–40. [PubMed] 126. Cuzick J, Terry G, Ho L, et al. Human papillomavirus type 16 DNA in cervical smears as predictor of high-grade cervical cancer. Lancet 1992;339:959–60. [PubMed] 127. Cuzick J, Terry G, Ho L, et al. Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br J Cancer 1994;69:167–71. [PMC free article] [PubMed] 128. Cuzick J, Szarewski A, Terry G, et al. Human papillomavirus testing in primary cervical screening. Lancet 1995;345:1533–6. [PubMed] 129. Cuzick J, Sasieni P, Davies P, et al. A systematic review of the role of human papillomavirus (HPV) testing within a cervical screening programme: summary and conclusions. Br J Cancer 2000;83:561–5. [PMC free article] [PubMed] 130. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000;9:945–51. [PubMed] 131. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293–9. [PubMed] 132. Clavel C, Masure M, Bory JP, et al. Hybrid capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer 1999;80:1306–11. [PMC free article] [PubMed] 133. Schiffman MH, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening. JAMA 2000;283:87–93. [PubMed] 134. Wright TC, Jr, Denny L, Kuhn L, et al. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000;283:81–6. [PubMed] 135. Hildesheim A, Gravitt P, Schiffman MH, et al. Determinants of genital human papillomavirus infection in low-risk women in Washington, DC. Sex Transm Dis 1993;20:279–84. [PubMed] 136. Wheeler CM, Parmenter CA, Hunt WC, et al. Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico student health center. Sex Transm Dis 1993;20:286–9. [PubMed] 137. Franco EL, Villa LL, Ruiz A, et al. Transmission of cervical human papillomavirus infection by sexual activity: differences between low- and high-risk oncogenic types. J Infect Dis 1995;172:756–63. [PubMed] 138. Muñoz N, Kato I, Bosch FX, et al. Risk factors for HPV DNA detection in middle-aged women. Sex Transm Dis 1996;23:504–10. [PubMed] 139. Sillins I, Kallings I, Dillner J. Correlates of the spread of human papillomavirus infection. Cancer Epidemiol Biomarkers Prev 2000;9:953–9. [PubMed] 140. Rousseau MC, Franco EL, Villa LL, et al. A cumulative case-control study of risk factor profiles for oncogenic and non-oncogenic cervical human papillomavirus infections. Cancer Epidemiol Biomarkers Prev 2000;9:469–76. [PubMed] 141. Kjaer SK, Chackerian B, Van den Brule AJC, et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 2001;10:101–6. [PubMed] 142. Barrasso R, de Brux J, Croissant O, et al. High prevalence of papillomavirus-associated penile intraepithelial neoplasia in sexual partners of women with cervical intraepithelial neoplasia. N Engl J Med 1987;317:916–23. [PubMed] 143. Kjaer SK, de Villiers EM, Dahl C, et al. Case-control study of risk factors for cervical neoplasia in Denmark. I: Role of the “male factor” in women with one lifetime sexual partner. Int J Cancer 1991;48:39–44. [PubMed] 144. Bergman A, Nalick R. Prevalence of human papillomavirus infection in men: comparison of the partners of infected and uninfected women. J Reprod Med 1992;37:710–12. [PubMed] 145. Bosch FX, Castellsagué X, Muñoz N, et al. Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. J Natl Cancer Inst 1996;88:1060–7. [PubMed] 146. Castellsagué X, Ghaffari A, Daniel RW, et al. Prevalence of penile human papillomavirus DNA in husbands of women with and without cervical neoplasia: a study in Spain and Colombia. J Infect Dis 1997;176:353–61. [PubMed] 147. de Sanjosé S, Palacio V, Tafur L, et al. Prostitution, HIV, and cervical neoplasia: a survey in Spain and Colombia. Cancer Epidemiol Biomarkers Prev 1993;2:531–5. [PubMed] 148. Thomas DB, Ray RM, Kuypers J, et al. Human papillomaviruses and cervical cancer in Bangkok. III. The role of husbands and commercial sex workers. Am J Epidemiol 2001;153:740–8. [PubMed] 149. Juarez-Figueroa LA, Wheeler CM, Uribe-Salas FJ, et al. Human papillomavirus: a highly prevalent sexually transmitted disease agent among female sex workers from Mexico City. Sex Transm Dis 2001;28:125–30. [PubMed] 150. Castellsagué X, Bosch FX, Muñoz N, et al. Male circumcision, penile human papillomavirus (HPV) infection and cervical cancer. N Engl J Med [In press.] [PubMed]
151. Rigoni-Stern. Fatti statistici relativi alle malattie cancerose. Giorn Prog Patol Terap 1842;2:507–17.
152. Beral V. Cancer of the cervix: a sexually transmitted infection? Lancet 1974;i:1037–40. [PubMed] 153. Skegg DC, Corwin PA, Paul C, et al. Importance of the male factor in cancer of the cervix. Lancet 1982;2:581–3. [PubMed] 154. Schiffman MH. New epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 1995;87:20. [PubMed] 155. Ylitalo N, Sorensen P, Josefsson AM, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000;355:2194–8. [PubMed] 156. van Duin M, Snijders PJF, Schrijnemakers HFJ, et al. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer [In press.] [PubMed] 157. Cubie H, Seagar A, McGoogan E, et al. Rapid real time PCR to distinguish between high risk human papillomavirus types 16 and 18. Mol Pathol 2001;54:24–9. [PMC free article] [PubMed]
158. Stern P, Duggan-Keen M. MHC expression in the natural history of cervical cancer In: Stern PL, Stanley MA, eds. Human papillomaviruses and cervical cancer. Biology and immunology. New York: Oxford University Press, 1994:162–76.
159. Tommasino M. Papillomaviruses in human cancer: the role of E6 and E7 oncoproteins. Austin, Texas: Landes Bioscience, 1997.
160. Lazo PA. The molecular genetics of cervical carcinoma. Br J Cancer 1999;80:2008–18. [PMC free article] [PubMed] 161. McGlennen RC. Human papillomavirus oncogenesis. Clin Lab Med 2000;20:383–404. [PubMed] 162. Woodworth CD, Doniger J, DiPaolo JA. Immortalization of human foreskin keratinocytes by various human papillomavirus DNAs corresponds to their association with cervical carcinoma. J Virol 1989;63:159–64. [PMC free article] [PubMed] 163. Meyers C, Laimins LA. In vitro systems for the study and propagation of human papillomaviruses. Curr Top Microbiol Immunol 1994;186:199–215. [PubMed] 164. Steenbergen RDM, Walboomers JMM, Meijer CJLM, et al. Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q. Oncogene 1996;13:1249–57. [PubMed] 165. Stoler MH, Rhodes CR, Whitbeck A, et al. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 1992;23:117–28 . [PubMed] 166. Lancaster WD, Castellano C, Santos C, et al. Human papillomavirus deoxyribonucleic acid in cervical carcinoma from primary and metastatic sites. Am J Obstet Gynecol 1986;154:115–19. [PubMed] 167. Schwarz E, Freese UK, Gissmann L, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985;314:111–14. [PubMed] 168. Durst M, Glitz D, Schneider A, et al. Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. Virology 1992;189:132–40. [PubMed] 169. Durst M, Kleinheinz A, Hotz M, et al. The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours. J Gen Virol 1985;66:1515–22. [PubMed] 170. Cullen AP, Reid R, Campion M, et al. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol 1991;65:606–12. [PMC free article] [PubMed] 171. Stanbridge EJ. Suppression of malignancy in human cells. Nature 1976;260:17–20. [PubMed] 172. Saxon PJ, Srivatsan ES, Stanbridge EJ. Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells. EMBO J 1986;5:3461–6. [PubMed] 173. Koi M, Morita H, Yamada H, et al. Normal human chromosome 11 suppresses tumorigenicity of human cervical tumor cell line SiHa. Mol Carcinog 1989;2:12–21. [PubMed] 174. Backsch C, Wagenbach N, Nonn M, et al. Microcell-mediated transfer of chromosome 4 into HeLa cells suppresses telomerase activity. Genes Chromosomes Cancer 2001;31:196–8. [PubMed] 175. Steenbergen RDM, Kramer D, Meijer CJLM, et al. Telomerase suppression by chromosome 6 in a human papillomavirus type 16-immortalized keratinocyte cell line and in a cervical cancer cell line. J Natl Cancer Inst 2001;93:865–72. [PubMed] 176. Dyson N, Howley PM, Munger K, et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934–6. [PubMed]
177. Lörincz AT. Human papillomaviruses. In: Lennette EH, Smith TF, eds. Laboratory diagnosis of viral infections. New York: Marcel Dekker, 1999:635–63.
178. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76–9. [PubMed] 179. Cheng S, Schmidt-Grimminger D-C, Murant T, et al. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev 1995;9:2335–49. [PubMed] 180. Jian Y, Schmidt-Grimminger D-C, Chien W-M, et al. Post-transcriptional induction of p21cip1 protein by human papillomavirus E7 inhibits unscheduled DNA synthesis reactivated in differentiated keratinocytes. Oncogene 1998;17:2027–38. [PubMed] 181. Schmidt-Grimminger D-C, Wu X, Jian Y, et al. Post-transcriptional induction of p21cip1 protein in condylomata and dysplasias is inversely related to human papillomavirus activities. Am J Pathol 1998;152:1015–24. [PubMed] 182. Steenbergen RDM, Parker JN, Isern S, et al. Viral E6-E7 transcription in the basal layer of organotypic cultures without apparent p21cip1 protein precedes immortalization of HPV 16 and HPV 18 transfected human keratinocytes. J Virol 1998;72:749–57. [PMC free article] [PubMed] 183. Stoler MH. Human papillomaviruses and cervical neoplasia: a model for carcinogenesis. Int J Gynecol Pathol 2000;19:16–28. [PubMed] 184. Hildesheim A, Schiffman MH, Tsukui T, et al. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease. Cancer Epidemiol Biomarkers Prev 1997;6:807–13. [PubMed] 185. Tsukui T, Hildesheim A, Schiffman MH et al. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res 1996;56:3697–74. [PubMed] 186. Chow LT, Broker TR. Papillomavirus DNA replication. Intervirology 1994;37:150–8. [PubMed] 187. Dollard SC, Wilson JL, Demeter LM, et al. Production of human papillomavirus and modulation of the infectious program in epithelial raft cultures. Genes Dev 1992;6:1131–42. [PubMed] 188. Flores ER, Lambert PF. Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral life cycle. J Virol 1997;71:7167–79. [PMC free article] [PubMed] 189. Munger K, Scheffner M, Huibregtse JM, et al. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. In: Levine AJ, ed. Tumour suppressor genes, the cell cycle and cancer. New York: Cold Spring Harbor Laboratory Press, 1992:197–217. [PubMed] 190. Turek LP, Smith EM. The genetic program of genital human papillomaviruses in infection and cancer. Obstet Gynecol Clin North Am 1996;23:735–58. [PubMed] 191. zur Hausen H. Roots and perspectives of contemporary papillomavirus research. J Cancer Res Clin Oncol 1996;122:3–13. [PubMed] 192. Tommasino M, Adamczewski JP, Carlotti F, et al. HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene 1993;8:195–202. [PubMed] 193. Demeter LM, Stoler MH, Broker TR, et al. Induction of proliferating cell nuclear antigen in differentiated keratinocytes of human papillomavirus-infected lesions. Hum Pathol 1994;25:343–8. [PubMed] 194. Stoler MH, Wolinsky SM, Whitbeck A, et al. Differentiation-linked human papillomavirus types 6 and 11 transcription in genital condylomata revealed by in situ hybridization with message-specific RNA probes. Virology 1989;172:331–40. [PubMed] 195. Arends MJ, Wyllie AH, Bird CC. Human papillomavirus type 18 is associated with less apoptosis in fibroblast tumours than human papillomavirus type 16. Br J Cancer 1995;72:646–9. [PMC free article] [PubMed] 196. Jones DL, Munger K. Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J Virol 1997;71:2905–12. [PMC free article] [PubMed] 197. McCance DJ, Kopan R, Fuchs E, et al. Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proc Natl Acad Sci U S A 1988;85:7169–73. [PubMed]
198. McDougall JK, Klingelhutz AJ. Telomerase and the HPV oncogenes: more than a terminal relationship. Papillomavirus Report 1999;10:81–4.
199. Jeon S, Allen-Hoffmann BL, Lambert PF. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol 1995;69:2989–97. [PMC free article] [PubMed] 200. zur Hausen H. Papillomavirus infections—a major cause of human cancers. Biochim Biophys Acta 1996;1288:F55–78. [PubMed] 201. Bauknecht T, See RH, Shi Y. A novel C/EBP beta-YY1 complex controls the cell-type-specific activity of the human papillomavirus type 18 upstream regulatory region. J Virol 1996;70:7695. [PMC free article] [PubMed] 202. Dong X-P, Stubenrauch F, Beyer-Finkler E, et al. Prevalence of deletions of YY1-binding sites in episomal HPV 16 DNA from cervical cancers. Int J Cancer 1994;58:803–8. [PubMed] 203. May M, Dong X-P, Beyer-Finkler E, Stubenrauch F, et al. The E6/E7 promoter of extrachromosomal HPV16 DNA in cervical cancers escapes from cellular repression by mutation of target sequences for YY1. EMBO J 1994;13:1460–6. [PubMed] 204. Kessis TD, Slebos RJ, Nelson WG, et al. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci U S A 1993;90:3988–92. [PubMed] 205. Scheffner M, Munger K, Byrne JC, et al. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci U S A 1991;88:5523–7. [PubMed] 206. Liotta LA, Kohn EC The microenvironment of the tumour-host interface. Nature 2001;411:375–9. [PubMed]
207. Saveria Campo M. Towards vaccines against papillomavirus. In: Stern PL, Stanley MA, eds. Human papillomaviruses and cervical cancer. Biology and immunology. New York: Oxford University Press, 1994:177–82.
208. Tindle RW. Vaccines for human papillomavirus infection and anogenital disease. Texas: RG Landes Company, 1999.
209. de Villiers EM. Taxonomic classification of papillomavirus. Papillomavirus Report 2001;12:57–63.
210. Riou G, Favre M, Jeannel D, et al. Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet 1990;335:1171–4. [PubMed] 211. Viladiu P, Bosch FX, Castellsague X, et al. Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer. J Clin Oncol 1997;15:610–19. [PubMed] 212. Tabrizi SN, Fairley ChK, Chen Sh, et al. Epidemiological characteristics of women with high grade CIN who do and do not have human papillomavirus. Br J Obstet Gynaecol 1999;106:252–7. [PubMed] 213. Burger MPM, Hollema H, Pieters WJLM, et al. Epidemiological evidence of cervical intraepithelial neoplasia without the presence of human papillomavirus. Br J Cancer 1996;73:831–6. [PMC free article] [PubMed] 214. Muñoz N, Bosch FX, Kaldor JM. Does human papillomavirus cause cervical cancer? The state of the epidemiological evidence. Br J Cancer 1988;57:1–5. [PMC free article] [PubMed] 215. Schiffman MH, Schatzkin A. Test reliability is critically important to molecular epidemiology: an example from studies of human papillomavirus infection and cervical neoplasia. Cancer Res 1994;54(suppl 7):1944s–7s. [PubMed] 216. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–9. [PubMed] 217. Deacon JM, Evans CD, Yule R, et al. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN 3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer 2000;88:1565–72. [PMC free article] [PubMed] 218. de Sanjose S, Muñoz N, Bosch FX, et al. Sexually transmitted agents and cervical neoplasia in Colombia and Spain. Int J Cancer 1994;56:358–63. [PubMed] 219. Bayo S, Bosch FX, de Sanjosé S, et al. Risk factors of invasive cervical cancer in Mali. Int J Cancer [In press.] [PubMed]
220. Moreno V, Bosch FX, Muñoz N, et al. Oral contraceptives and cervical cancer: pooled analysis of the IARC multicentric case-control study. Lancet [In press.]
221. Kjaer SK, van den Brule AJC, Svare EI, et al. Different risk factor patterns for high-grade and low-grade intraepithelial lesions on the cervix among HPV-positive and HPV-negative young women. Int J Cancer 1998;76:613–9. [PubMed] 222. Lacey JV, Brinton LA, Abbas FM, et al. Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 1999;8:1079–85. [PubMed]
223. IARC. Hormonal contraception and post-menopausal hormonal therapy. IARC monographs on the evaluation of carcinogenic risks to humans, Vol. 72. Lyon: IARC, 1999.
224. Muñoz N, Franceschi S, Bosch FX, et al. The influence of reproductive and menstrual factors on cervical cancer in HPV-positive women. Lancet [In press.]
225. Hildesheim A, Herrero R, Castle PE, et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer 2001;84:1219–26. [PMC free article] [PubMed] 226. Kjaer SK, de Villiers EM, Haugaard BJ, et al. Human papillomavirus, herpes simplex virus and cervical cancer incidence in Greenland and Denmark. A population-based cross-sectional study. Int J Cancer 1988;41:518–24. [PubMed] 227. Ferrera A, Velema JP, Figueroa M, et al. Co-factors related to the causal relationship between human papillomavirus and invasive cervical cancer in Honduras. Int J Epidemiol 2000;29:817–25. [PubMed] 228. Winkelstein W, Jr. Smoking and cancer of the uterine cervix: hypothesis. Am J Epidemiol 1977;106:257–9. [PubMed] 229. IARC. Tobacco smoking. Lyon: IARC monographs on the evaluation of carcinogenic risks to humans, Vol. 38. Lyon: IARC, 1986. [PubMed]
230. Szarewski A, Cuzick J. Smoking and cervical neoplasia: a review of the evidence. J Epidemiology and Biostatistics 1998;3:229–56.
231. Surgeon General's Advisory Committee on Women and Smoking. Public Health Service, 2001. (Available online:http://www.cdc.gov/tobacco.) 232. Kjaer SK. Risk factors for cervical neoplasia in Denmark. APMIS 1998;80:1–41. [PubMed] 233. Beasley RP, Trepo C, Stevens CE, et al. The E antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977;105:94–8. [PubMed] 234. Coursaget P, Yvonnet B, Chotard J, et al. Age and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J Med Virol 1987;22:1–5. [PubMed]
235. Evans AS, Niederman JC. Epstein-Barr virus. In: Evans AS ed. Viral infections of humans, 3rd ed. New York: Plenum, 1989:265–92.
236. Smith JS, Muñoz N, Herrero R, et al. Evidence for Chlamydia trachomatis as an HPV cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis 2002;185:324–31. [PubMed] 237. Castle PE, Hillier SL, Rabe LK, et al. An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev 2001;10:1021–7. [PubMed] 238. de Sanjose S, Bosch FX, Muñoz N, et al. Social differences in sexual behaviour and cervical cancer. In: Kogevinas M, Pearce N, Susser M, et al, eds. Social inequalities and cancer. Lyon: IARC Scientific Publications, 1997. (No. 138):309–17. [PubMed] 239. Potischman L, Brinton LA. Nutrition and cervical neoplasia. Cancer Causes Control 1996;7:113–26. [PubMed] 240. Storey A, Thomas M, Kalita A, et al. Role of p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229–34. [PubMed] 241. Makni H, Franco E, Kaiano J, et al. p53 polymorphism in codon 72 and risk of HPV-induced cervical cancer: effect of interlaboratory variation. Int J Cancer 2000;87:528–33. [PubMed] 242. Madeleine MM, Shera K, Schwartz SM, et al. The p53 Arg72Pro polymorphism, human papillomavirus, and invasive squamous cell cervical cancer. Cancer Epidemiol Biomarkers Prev 2000;9:225–7. [PubMed] 243. Rezza G, Giuliani M, Garbuglia AR, et al. Lack of association between p53 codon-72 polymorphism and squamous intraepithelial lesions in women with, or at risk for, human immunodeficiency virus and/or human papillomavirus infections. Cancer Epidemiol Biomarkers Prev 2001;10:565–6. [PubMed] 244. Zehbe I, Voglino G, Wilander E, et al. p53 codon 72 polymorphisms and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res 2001;61:608–11. [PubMed] 245. Koskela P, Antilla T, Biorge T, et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 2000;85:35–9. [PubMed] 246. van den Brule AJC, Kjaer SK, Munk C, et al. Development of HPV induced cervical intraepithelial neoplasias: infection with Chlamdya trachomatis as a possible cofactor. In: Castellsagué X, Bosch FX, de Sanjosé S, et al, eds. 18th International Papillomavirus Conference—program and abstracts book. Barcelona: Thau SL, 2000:130 (available on line: http:/www.hpv2000.com). 247. Villa LL, Franco EL. Epidemiologic correlates of cervical neoplasia and risk of human papillomavirus infection in asymptomatic women in Brazil. J Natl Cancer Inst 1989;81:332–40. [PubMed] 248. Guerrero E, Daniel RW, Bosch FX, et al. Comparison of ViraPap, Southern hybridization, and polymerase chain reaction methods for human papillomavirus identification in an epidemiological investigation of cervical cancer. J Clin Microbiol 1992;33:2229. [PMC free article] [PubMed] 249. zur Hausen H. Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer. J Natl Cancer Inst 2001;93:252–3. [PubMed] 250. Bosch FX, Muñoz N, de Sanjosé S, et al. Re: cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer. J Natl Cancer Inst 2001;93:1349–50. [PubMed]
251. IARC. Human papillomavirus and cervical cancer. Muñoz N, Bosch FX, Jensen OM, eds. Lyon: IARC Scientific Publications, Vol. 94, 1989.
252. IARC. The epidemiology of cervical cancer and human papillomavirus. Muñoz N, Bosch FX, Shah KV, et al, eds. Lyon: IARC Scientific Publications, Vol. 119, 1992.
253. Meijer CJLM, Brule AJC van den, Snijders PJF, et al. Detection of human papilloma virus in cervical scrapes by the polymerase chain reaction in relation to cytology: possible implications for cervical cancer screening. In: Muñoz N, Bosch FX, Shah KV, Meheus A, eds. The epidemiology of cervical cancer and human papillomavirus. Lyon: IARC, 1992:271–81. [PubMed] 254. Cuzick J, Beverley E, Ho L, et al. HPV testing in primary screening of older women. Br J Cancer 1999;81:554–8. [PMC free article] [PubMed] 255. Coutlée F, Gravitt P, Richardson H, et al. Nonisotopic detection and typing of human papillomavirus DNA in genital samples by the line blot assay. J Clin Microbiol 1999;37:1852–7. [PMC free article] [PubMed] 256. Sellors JW, Mahony JB, Kaczorowski J, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Can Med Assoc J 2000;163:503–8. [PMC free article] [PubMed] 257. Meijer CJLM, Walboomers JMM. Cervical cytology after 2000: where to go? J Clin Pathol 2000;53:41–3. [PMC free article] [PubMed] 258. The Atypical Squamous Cell of Undetermined Significance/Low-grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000;92:397–402. [PubMed] 259. Follen M, Richards-Kortum R. Emerging technologies and cervical cancer. J Natl Cancer Inst 2000;92:363–65. [PubMed] 260. Sasieni PD. Human papillomavirus screening and cervical cancer prevention. J Am Med Wom Assoc 2000;55:216–19. [PubMed] 261. Stevenson , Hudson LC, Burns JE, et al. Inverse relationship between the expression of the human papillomavirus type 16 transcription factor E2 and virus DNA copy number during the progression of cervical intraepithelial neoplasia. J Gen Virol 2000;81:1825–32. [PubMed] 262. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18 and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911–19. [PubMed] 263. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. Can Med Assoc J 2001;164:1017–25. [PMC free article] [PubMed] 264. Lehtinen M, Luukkaala T, Wallin K-L, et al. Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction. J Clin Virol 2001;22:117–24. [PubMed] 265. Anttila T, Saiku P, Koskela P, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001;285:47–51. [PubMed] 266. Andersson S, Rylander E, Larsson B, et al. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer 2001;37:246–50. [PubMed] 267. Clavel C, Masure M, Bory J-P, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001;84:1616–23. [PMC free article] [PubMed] 268. Goldie SJ, Kuhn L, Denny L, et al. Policy analysis of cervical cancer screening strategies in low-resource settings. Clinical benefits and cost-effectiveness. JAMA 2001;285:3107–15. [PubMed] 269. Schwartz SM, Daling JR, Shera KA, et al. Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol 2001;19:1906–15. [PubMed] 270. Liaw K-L, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001;183:8–15. [PubMed] 271. Gravitt PE, Lacey JV, jr, Brinton LA, et al. Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. Cancer Epidemiol Biomarkers Prev 2001;10:95–100. [PubMed] 272. Harro CD, Pang Y-YS, Roden RBS, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001;93:284–92. [PubMed] 273. Peyton CL, Gravitt PE, Hunt WC, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis 2001;183:1554–64. [PubMed]
274. Multiple authors. From epidemiology to policy: a symposium on the translation of epidemiologic evidence into public health policy. Am J Epidemiol (Special Issue) 2001;154.
275. Lanes S. Causal inference is not a matter of science. Am J Epidemiol 1985;122:550.
276. Rothman KJ, Poole C. Science and policy making. Am J Public Health 1985;75:340–1. [PubMed]